Clonidine is used to treat high blood pressure by helping blood vessels relax and reducing heart rate. It is also used to help manage ADHD symptoms in children and to reduce hot flashes in menopausal women.[2] Catapres is currently approved and in use across 41 indications[4].[1]
Catapres is one of 755 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
198 competitors in Heart Failure
Catapres
Bayer Aspirin
Brethine
Medrol
Amidate
Activase
Zemplar
Adriamycin
Savaysa
Xifaxan
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
CATAPRES
NDA NDA017407
Oct 10, 1984
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Oct 10, 1984
CATAPRES-TTS-1
NDA NDA018891
Sep 18, 1985
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Oct 14, 1987
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
May 11, 1988
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
May 11, 1988
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Jul 21, 1988
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Oct 27, 1988
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Dec 7, 1988
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Apr 18, 1989
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Dec 13, 1989
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Aug 17, 1992
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Nov 24, 1992
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Feb 19, 1993
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Jun 9, 1995
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Jul 23, 1996
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Jul 23, 1996
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Sep 6, 1996
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Sep 6, 1996
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Oct 2, 1996
DURACLON
NDA NDA020615
Oct 3, 1997
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Sep 22, 1998
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Aug 30, 1999
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Aug 13, 2004
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Apr 13, 2006
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Sep 30, 2009
JENLOGA
NDA NDA022331
Nov 13, 2009
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Dec 3, 2009
NEXICLON XR
NDA NDA022500
Dec 3, 2009
CLONIDINE
NDA NDA022499
Apr 28, 2010
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
May 31, 2012
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Feb 1, 2023
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
May 24, 2024
ONYDA XR
NDA NDA217645
Oct 23, 2025
JAVADIN
NDA NDA220256
Dec 4, 2025
CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
NDA NDA018891
Jul 28, 2026
QLONILIK
NDA NDA221094
Sources
Details